MOTS-c for women: what the science says vs. TikTok claims

What's this video probably claiming?

Based on the caption structure, @peptides.fyi is almost certainly walking viewers through a week-by-week timeline of MOTS-c effects in women, covering energy levels, body composition changes, and metabolic markers. This format is common in peptide content and implies a predictable, measurable progression. The creator is likely referencing anecdotal protocols, possibly suggesting specific phases of response: early energy shifts in weeks one to two, body composition changes around weeks three to four, and metabolic improvements by week six or beyond. The hashtag combination of #PeptidesForWomen and #WomensHealth suggests the content is framed specifically around female physiology, possibly referencing hormonal interactions or menopause-related metabolism. The link to an external peptide guide is a common monetization and lead-generation pattern. None of this is inherently wrong, but week-by-week timelines for MOTS-c in women specifically are not grounded in clinical trial data as of 2024.

What does the science actually show?

MOTS-c is a mitochondria-derived peptide, encoded in the mitochondrial 12S rRNA gene, first described by Lee et al. in 2015 in Cell Metabolism. That original mouse study showed MOTS-c improved insulin sensitivity and reduced obesity when administered at 15 mg/kg in high-fat diet models. A 2021 follow-up by Reynolds et al. in Nature Communications found that MOTS-c levels decline with age in humans and that exogenous administration in aged mice improved exercise capacity and metabolic function. Importantly, a 2023 study by Zempo et al. in GeroScience identified sex-specific differences in circulating MOTS-c, with higher baseline levels in premenopausal women compared to men of the same age. However, none of these are human clinical trials of exogenous MOTS-c supplementation or injection in women. The leap from mouse pharmacology to a human week-by-week response guide is large, and the creator is almost certainly not acknowledging that gap.

Where does the social media noise diverge from clinical reality?

The week-by-week format is the core problem here. It implies a clinical certainty that does not exist. There are no published randomized controlled trials of exogenous MOTS-c administration in human women, full stop. The doses circulating in biohacking communities, typically 5 to 10 mg subcutaneous injection several times per week, are extrapolated from mouse studies using weight-adjusted conversions that pharmacologists consider unreliable across species. Body composition claims are particularly suspect. Rodent fat mass reductions seen with MOTS-c cannot be translated into human timelines without Phase II trial data, which does not yet exist for this compound. The framing around metabolic markers, likely referencing fasting glucose, insulin, or HOMA-IR, is plausible as a hypothesis but presenting it as an expected week-by-week progression for women is misleading. It conflates mechanistic plausibility with demonstrated clinical efficacy. Social media peptide content routinely does this, and it matters because women may be self-administering unregulated compounded or gray-market peptides based on this kind of content.

What should you actually know?

MOTS-c is genuinely interesting science. The mitochondrial origin, the exercise-mimetic properties, and the age-related decline pattern are all compelling research directions. But interesting preliminary data is not the same as proven therapy. The Zempo et al. 2023 data on sex differences in endogenous MOTS-c is particularly relevant for women, but it describes what happens to circulating peptide levels, not what happens when you inject synthetic MOTS-c. Regulatory status matters here too. MOTS-c is not FDA-approved for any indication. It is not on the FDA's 503A or 503B approved compounding lists for peptides, which means compounded versions exist in a legally ambiguous space in most jurisdictions. Any creator building a week-by-week use guide without disclosing this regulatory context is giving viewers an incomplete picture. If you are considering MOTS-c, that conversation belongs with a physician who can review your metabolic baseline, not a TikTok timeline.